Next Article in Journal
Transformation of Riccia fluitans, an Amphibious Liverwort Dynamically Responding to Environmental Changes
Previous Article in Journal
Paternal Exposure to Bisphenol-A Transgenerationally Impairs Testis Morphology, Germ Cell Associations, and Stemness Properties of Mouse Spermatogonial Stem Cells
Previous Article in Special Issue
MSX1—A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas
Open AccessArticle

The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer

School of Pharmacy, University of Camerino, 62032 Camerino (MC), Italy
Gynecological Oncology Department LKI, Leuven Cancer Institute KU, Leuven-University of Leuven, 3000 Leuven, Belgium
School of Bioscience and Veterinary Medicine, University of Camerino, 62032 Camerino (MC), Italy
Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute (AvL-NKI), University Medical Centra (UMC), 1066 Amsterdam, The Netherlands
Oncologia Medica, Ospedale di San Severino, 62027 San Severino Marche (MC), Italy
Department of Molecular Medicine, Sapienza University, 00155 Rome, Italy
Integrative Therapy Discovery Lab, University of Camerino, 62032 Camerino (MC), Italy
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2020, 21(15), 5409;
Received: 29 June 2020 / Revised: 23 July 2020 / Accepted: 29 July 2020 / Published: 29 July 2020
Several studies support, both in vitro and in vivo, the anti-cancer effects of cannabidiol (CBD), a transient receptor potential vanilloid 2 (TRPV2) ligand. TRPV2, often dysregulated in tumors, is associated with altered cell proliferation and aggressiveness. Endometrial cancer (EC) is historically divided in type I endometrioid EC and type II non-endometrioid EC, associated with poor prognosis. Treatment options with chemotherapy and combinations with radiation showed only limited efficacy. Since no data are reported concerning TRPV2 expression as well as CBD potential effects in EC, the aim of this study was to evaluate the expression of TRPV2 in biopsies and cell lines as well as the effects of CBD in in vitro models. Overall survival (OS), progression-free survival (PFS), cell viability, migration, and chemo-resistance have been evaluated. Results show that TRPV2 expression increased with the malignancy of the cancer tissue and correlated with shorter PFS (p = 0.0224). Moreover, in vitro TRPV2 over-expression in Ishikawa cell line increased migratory ability and response to cisplatin. CBD reduced cell viability, activating predominantly apoptosis in type I cells and autophagy in mixed type EC cells. The CBD improved chemotherapeutic drugs cytotoxic effects, enhanced by TRPV2 over-expression. Hence, TRPV2 could be considered as a marker for optimizing the therapy and CBD might be a useful therapeutic option as adjuvant therapy. View Full-Text
Keywords: cannabidiol; TRPV2; endometrial cancer; progression-free survival; migration; chemo-resistance cannabidiol; TRPV2; endometrial cancer; progression-free survival; migration; chemo-resistance
Show Figures

Graphical abstract

MDPI and ACS Style

Marinelli, O.; Morelli, M.B.; Annibali, D.; Aguzzi, C.; Zeppa, L.; Tuyaerts, S.; Amantini, C.; Amant, F.; Ferretti, B.; Maggi, F.; Santoni, G.; Nabissi, M. The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer. Int. J. Mol. Sci. 2020, 21, 5409.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop